Skip to main content

Dactinomycin Dosage

Medically reviewed by Drugs.com. Last updated on May 3, 2024.

Applies to the following strengths: 0.5 mg

Usual Adult Dose for Wilms' Tumor

As part of a multi-agent combination chemotherapy regimen: 45 mcg/kg IV over 10 to 15 minutes once every 3 to 6 weeks for up to 26 weeks

Use: For the treatment of Wilms tumor as part of a multi-phase combination chemotherapy regimen

Usual Adult Dose for Rhabdomyosarcoma

As part of a multi-agent combination chemotherapy regimen: 15 mcg/kg IV over 10 to 15 minutes once daily for 5 days every 3 to 9 weeks for up to 112 weeks

Use: For the treatment of rhabdomyosarcoma as part of a multi-phase combination chemotherapy regimen

Usual Adult Dose for Ewing's Sarcoma

As part of a multi-agent combination chemotherapy regimen: 1250 mcg/m2 IV over 10 to 15 minutes once every 3 weeks for 51 weeks

Use: For the treatment of Ewing sarcoma as part of a multi-phase combination chemotherapy regimen

Usual Adult Dose for Testicular Cancer

As part of a cisplatin-based multi-agent combination chemotherapy regimen: 1000 mcg/m2 IV over 10 to 15 minutes once every 3 weeks for 12 weeks

Use: For the treatment of metastatic nonseminomatous testicular cancer as part of a multi-phase combination chemotherapy regimen

Usual Adult Dose for Trophoblastic Disease

As a single agent for nonmetastatic and low-risk metastatic disease: 12 mcg/kg IV over 10 to 15 minutes daily for 5 days

As part of a multi-agent combination chemotherapy regimen for high-risk metastatic disease: 500 mcg IV over 10 to 15 minutes Days 1 and 2 every 2 weeks for up to 8 weeks

Use: For the treatment of post-menarchal patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimen

Usual Adult Dose for Solid Tumors

In combination with melphalan for lower extremity or pelvis: 50 mcg/kg IV over 10 to 15 minutes once

In combination with melphalan for upper extremity: 35 mcg/kg IV once

Use: For the treatment of adult patients with locally recurrent or locoregional solid malignancies as a component of palliative or adjunctive regional perfusion

Usual Pediatric Dose for Wilms' Tumor

As part of a multi-agent combination chemotherapy regimen: 45 mcg/kg IV over 10 to 15 minutes once every 3 to 6 weeks for up to 26 weeks

Use: For the treatment of Wilms tumor as part of a multi-phase combination chemotherapy regimen

Usual Pediatric Dose for Rhabdomyosarcoma

As part of a multi-agent combination chemotherapy regimen: 15 mcg/kg IV over 10 to 15 minutes once daily for 5 days every 3 to 9 weeks for up to 112 weeks

Use: For the treatment of rhabdomyosarcoma as part of a multi-phase combination chemotherapy regimen

Usual Pediatric Dose for Ewing's Sarcoma

As part of a multi-agent combination chemotherapy regimen: 1250 mcg/m2 IV over 10 to 15 minutes once every 3 weeks for 51 weeks

Use: For the treatment of Ewing sarcoma as part of a multi-phase combination chemotherapy regimen

Usual Pediatric Dose for Testicular Cancer

As part of a cisplatin-based multi-agent combination chemotherapy regimen: 1000 mcg/m2 IV over 10 to 15 minutes once every 3 weeks for 12 weeks

Use: For the treatment of metastatic nonseminomatous testicular cancer as part of a multi-phase combination chemotherapy regimen

Usual Pediatric Dose for Trophoblastic Disease

As a single agent for nonmetastatic and low-risk metastatic disease: 12 mcg/kg IV over 10 to 15 minutes daily for 5 days

As part of a multi-agent combination chemotherapy regimen for high-risk metastatic disease: 500 mcg IV over 10 to 15 minutes Days 1 and 2 every 2 weeks for up to 8 weeks

Use: For the treatment of post-menarchal pediatric patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimen

Renal Dose Adjustments

Renal dysfunction may occur. Monitor creatinine and electrolytes frequently.

Liver Dose Adjustments

Hepatic dysfunction may occur. Monitor creatinine and electrolytes frequently during therapy.

Dose Adjustments

Calculate the dose for obese or edematous patients based on ideal body weight.

Precautions

CONTRAINDICATIONS:


Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Reconstitution/preparation techniques:

IV compatibility:

General:

Monitoring:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.